Biotech Startups

SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.

3 investors

SphingoTec develops proprietary biomarkers for critical care diagnostics, addressing acute kidney injury, sepsis, and acute heart failure through partnerships with in vitro diagnostics companies and pharmaceutical firms. The company licenses its biomarker portfolio to global IVD partners to make clinical diagnostic products available worldwide.

3 investors

Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform. Its lead program, SPT-2101, is a sustained-release dexamethasone formulation for treating Ménière's disease.

3 investors

Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases. The company develops proprietary linker-payloads and offers ADC design and conjugation expertise for partnering with pharmaceutical and biotech companies.

3 investors

Spora discovers and cultivates wild fungal strains from pristine ecosystems, processing them with proprietary biotechnology and nanotechnology to create mycelium-based products. The company combines scientific research with ancestral knowledge from remote communities to develop sustainable, nature-inspired solutions.

3 investors

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.

3 investors

Spur Therapeutics develops gene therapy treatments for genetic diseases, aiming to bring genetic medicine therapies to patients worldwide.

3 investors

SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.

3 investors

SQIM is a material innovation company that uses living organisms and organic matter (biofabrication) to produce alternative materials. It operates two product brands: Ephea, which makes mycelium-based materials for fashion, and Mogu, which makes materials for interior design and architecture.

3 investors

3 investors

STAQ Pharma is an FDA-registered 503B outsourcing facility that compounds and supplies medications to hospitals and healthcare providers across the United States, aiming to address drug shortages. The company is owned and guided by several healthcare systems and focuses on safety, transparency, availability, and quality.

3 investors

Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways. The company serves life science researchers and laboratories.

3 investors

Stately Bio develops stem cell-derived regenerative and cell therapies using a machine learning platform that measures cell identity, behavior, and maturation directly from live-cell, label-free imaging. It partners with institutions and companies in the cell therapy field to support therapy discovery and manufacturing.

3 investors

28bio (formerly StemoniX Medical Tech) develops human induced-pluripotent-stem-cell-derived 3D neural organoid platforms, including CNS and PNS models, used to measure human neural activity in vitro. The company offers products and services for drug safety assessment, such as seizure liability and neurotoxicity testing, and efficacy research in areas like neuroinflammation, myelination and Alzheimer's disease.

3 investors

Strand AI predicts missing biological data modalities from existing patient data, converting single histopathology slides into spatial protein maps and inferring gene expression from genotype. The platform serves researchers and clinicians in computational pathology and genomics.

3 investors

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

3 investors

StrataGen Bio develops technology to convert MRI scans into quantitative biomarker measurements for objective clinical decision-making. The company operates in the medical imaging and diagnostics space.

3 investors

StratifAI develops AI-driven multimodal biomarkers for precision oncology, using its platform to link routine H&E histology and RNASeq gene expression data to patient outcomes for prognostic and predictive insights. Its offerings target cancer diagnostics for oncology institutions and pharmaceutical companies, with an initial focus on breast cancer recurrence risk.

3 investors

String Bio develops technology at the intersection of biology, engineering, and chemistry to produce next-generation ingredients addressing challenges in food, feed, health, and the environment. The company operates a proprietary technology platform and a product portfolio aimed at sustainable and scalable bio-based solutions.

3 investors

Sunflower Therapeutics develops next-generation biomanufacturing technologies to reduce the complexity and cost of bringing biologic medicines to market. The platform serves entrepreneurs and established companies developing protein-based therapeutics, biomaterials, and related health and wellness products.

3 investors

SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.

3 investors

SweetBio develops wound care dressings that combine collagen and Mānuka honey to help close chronic and acute non-healing wounds. Its products are used in clinical wound care settings and are reimbursed by Medicare, commercial plans, and available in VA and Department of Defense facilities.

3 investors

Switch Bioworks develops biology-based fertilizer as an alternative to conventional chemical fertilizers, using synthetic biology and microbial discovery. Its work targets agriculture and crop production, aiming to provide affordable fertilizer with lower environmental impact.

3 investors

Switchback Systems develops a benchtop DNA synthesis platform that combines onboard oligonucleotide synthesis and gene assembly, aimed at putting synthetic biology tools directly in scientists' hands. It targets researchers across industries such as pharmaceuticals, agriculture, and plastics, positioning itself in the synthetic biology and DNA synthesis market.

3 investors